[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"EyePoint Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627538","phase-3-como-a-phase-3-randomized-double-masked-study-comparing-the-efficacy-of-eyp-1901-against-aflibercept-in-dme-100627538",false,"NCT07449936","COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)","DME","Inclusion Criteria:\n\n* Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.\n* Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20\u002F200 Snellen equivalent) to 78 letters (20\u002F32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).\n* For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.\n\nExclusion Criteria:\n\n* BCVA using ETDRS charts \\\u003C30 letters (20\u002F250 Snellen equivalent) in the fellow eye.","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.",[27,15,28],"Diabetic Macular Edema","Diabetic Macular Edema (DME)",[30,31,32,27],"EyePoint","EYP-1901","Tyrosine Kinase Inhibitor","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":37},"2026-02-16",{"date":41,"type":21},"2028-10",{"name":43,"class":44},"EyePoint Pharmaceuticals, Inc.","INDUSTRY",65,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":25,"conditions":53,"keywords":54,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":60},"100627537","phase-3-capri-a-phase-3-randomized-double-masked-study-comparing-the-efficacy-of-eyp-1901-against-aflibercept-in-dme-100627537","NCT07449923","CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME",{"count":20,"type":21},[24],[27,15,28],[30,32,27,31],{"date":36,"type":37},{"date":57,"type":37},"2026-02-09",{"date":41,"type":21},{"name":43,"class":44},62,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100453989","phase-4-evaluate-the-safety-of-dexycu-for-the-treatment-of-inflammation-following-ocular-surgery-for-childhood-cataract-100453989","NCT05191706","Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","Inclusion Criteria:\n\n* Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation.\n* If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content).\n* Other protocol-specified inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the investigator.\n* Has a post-traumatic cataract.\n* Presence of active or suspected viral, bacterial, or fungal disease in the study eye.\n* Ocular hypertension with an IOP in the study eye \\>25 mmHg at Screening with or without treatment with anti-glaucoma monotherapy.\n* Subjects who have received a periocular corticosteroid injection in the study eye in the 3 months prior to Screening.\n* Subjects who have received any intravitreal corticosteroid delivery vehicle (eg, Retisert®, Ozurdex®, Iluvien®) in the study eye at any time.\n* Other protocol-specified exclusion criteria may apply","3 Years",{"count":70,"type":21},60,[72],"PHASE4","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",[75],"Cataract",[77,78],"pediatric","cataract","2025-04-01",{"date":81,"type":37},"2025-04-03",{"date":83,"type":37},"2022-01-04",{"date":85,"type":21},"2026-02",{"name":43,"class":44},9,""]